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The transcription factor NURR1 plays a pivotal role in the development and maintenance of
neurotransmitterphenotypeinmidbraindopamineneurons.Conversely,decreasedNURR1
expression is associated with a number of dopamine-related CNS disorders, including
Parkinson’s disease and drug addiction. In order to better understand the nature of NURR1-
responsive genes and their potential roles in dopamine neuron differentiation and survival,
we used a human neural cellular background (SK-N-AS cells) in which to generate a num-
ber of stable clonal lines with graded NURR1 gene expression that approximated that
seen in DA cell-rich human substantia nigra. Gene expression proﬁling data from these
NURR1-expressing clonal lines were validated by quantitative RT-PCR and subjected to
bioinformatic analyses.The present study identiﬁed a large number of NURR1-responsive
genes and demonstrated the potential importance of concentration-dependent NURR1
effectsinthedifferentialregulationofdistinctNURR1targetgenesandbiologicalpathways.
These data support the promise of NURR1-based CNS therapeutics for the neuroprotection
and/or functional restoration of DA neurons.
Keywords: NURR1, transcription factor, gene expression proﬁle, neurodegeneration, addiction, dopamine cell,
human
INTRODUCTION
Nuclear receptor related 1 (NURR1; also known as NR4A2, NOT,
TINUR,HZF3,RNR1),togetheralongwithNUR77(NR4A1)and
NOR-1 (NR4A3), constitute the NR4A family of orphan nuclear
receptors.Dependingonthecellularcontext,thesetranscriptional
regulators may be stably expressed or induced as immediate early
genes, leading to pleiotropic physiological effects (Maxwell and
Muscat,2005).NURR1playsauniqueandcriticalroleinthedevel-
opment of the dopaminergic neurotransmitter phenotype in ven-
tralmidbrainneurons,asevidencedbythelossof dopamine(DA)
phenotypic markers in Nurr1-null mice (Zetterstrom et al., 1997;
Castillo et al., 1998; Saucedo-Cardenas et al., 1998). Moreover,
continued Nurr1 expression is required for phenotypic mainte-
nance in mature DA neurons (Kadkhodaei et al.,2009). In animal
and cellular studies, modest changes in NURR1 levels affect the
resilience of DA cells in response to stressors, drugs, and neuro-
toxins (Le et al., 1999; Eells et al., 2002; Moore et al., 2008). In
keeping with these ﬁndings from model systems, in human brain
decreasedNURR1geneexpressionisassociatedwithadiminution
of DA phenotype during normal aging, as well as in Parkinson’s
disease (PD), and chronic drug abuse (Bannon et al., 2002; Chu
etal.,2002;Horvathetal.,2007;Leetal.,2008;Sleimanetal.,2009).
Despitetherecognitionof NURR1’simportance,ourunderstand-
ing of the full complement of NURR1-responsive genes and their
roles in the differentiation and survival of DA neurons is far from
complete.
The identiﬁcation of genes regulated by NURR1 has come
aboutlargelybydeterminingchangesinmidbraingeneexpression
occurring in the Nurr1-null mouse or by acute over-expression of
NURR1 in various cell lines (Sacchetti et al., 1999, 2001; Iwawaki
et al., 2000; Wallen et al., 2001; Hermanson et al., 2003, 2006;
Lammi et al., 2004; Davies et al., 2005; Gil et al., 2007; Kitagawa
etal.,2007;Luoetal.,2007;Sousaetal.,2007;Volpicellietal.,2007;
Yang and Latchman, 2008; Jacobs et al., 2009a; Galleguillos et al.,
2010). Surprisingly, there seems to be quite limited concordance
among these datasets, exempliﬁed by a recent study (Jacobs et al.,
2009a) in which only one in eight genes differentially expressed
in the Nurr1-null midbrain was also affected by transient NURR1
over-expressioninamouse-derivedcellmodelsystem(withmany
of theaffectedtranscriptsshowingsimilardirectionalityof change
after both the loss of NURR1 and NURR1 over-expression). When
considering such discrepancies, one must consider the impor-
tance of cellular background (with attendant differences in the
expression of transcriptional regulators and other genes). Given
the growing appreciation, however, that some transcription fac-
torscanexertconcentration-dependenteffectsongeneexpression
(Johnson et al., 2006; Kamath et al., 2008; Pope and Bresnick,
2010), we hypothesized that the proﬁles of NURR1-responsive
genescouldalsovaryasafunctionof theNURR1expressionlevels
in these various model systems.
Inordertobeginaddressingpossibleconcentration-dependent
effects of NURR1 on target gene response, and to avoid the
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confounding issue of cell-to-cell heterogeneity of transgene
expression that is seen with transient transfections, we chose a
well-characterized human neuronal cell line (SK-N-AS cells) with
modest basal expression of NURR1 as the cellular background in
which to generate a number of clonal cell lines with stable,graded
levels of NURR1 expression. Using gene expression proﬁling,
quantitative RT-PCR, and bioinformatics, we identiﬁed distinct
concentration-dependent effects of NURR1 on individual target
genes and biological pathways. Implications for the therapeutic
use of NURR1 in the treatment of CNS disorders related to DA
neuron dysfunction are discussed.
MATERIALS AND METHODS
DERIVATION OF SK-N-AS CLONAL CELL LINES AND CELL CULTURE
PROCEDURES
ThehumanneuroblastomacelllineSK-N-AS(AmericanTypeTis-
sueCollection,Manassas,VA,USA),wasmaintainedaspreviously
described (Michelhaugh et al., 2005; Wang and Bannon, 2005;
Wangetal.,2007).Togeneratestableclonalcelllines,parentalSK-
N-AS cells were transfected with 10μg of a previously described
(Michelhaughetal.,2005)NURR1expressionconstruct(orcorre-
sponding empty vector) using LipofectAMINE2000 (Invitrogen)
following the manufacturer’s protocol. Cells expressing transgene
(including the neomycin resistance gene) were selected for by
treatment with the antibiotic G418 (1μg/mL), then harvested,
and replated at very low density in 96 well plates to allow for
subsequent harvest and expansion of single stably transfected
cells into distinct clonal cell lines, which were screened for the
level of NURR1-encoding transgene expression (independent of
transgene copy number or potential integration site). In a sep-
arate experiment, the MN9D-derived, dox-inducible, NURR1-
expressingcelllineMN9D-23(providedbyDr.HowardJ.Federoff,
Georgetown, USA) was grown as previously described (Luo et al.,
2007) and treated with doxycycline (2μg/mL; Sigma, USA) for
24hbeforeharvest.SK-N-AS-derivedclonallinesandMN9Dcells
were assessed for NURR1 expression as described below.
RNA ISOLATION AND qRT-PCR
RNA was isolated using TRIzol reagent (Invitrogen) following
the manufacturer’s protocol, then DNAse-treated with the Qia-
gen RNeasy Minikit (Qiagen,Valencia, CA, USA). Quantiﬁcation
of RNA was accomplished using NanoDrop ND-1000 (Thermo
Scientiﬁc, Waltham, MA, USA), with an initial assessment of
RNA quality by agarose–formaldehyde gel electrophoresis and
ethidium bromide staining. RNA (100ng) from each sample was
reverse-transcribed using random hexamers (Promega, Madison,
WI, USA) and Omniscript RT kit (Qiagen) following the manu-
facturer’s protocol. Subsequent PCR reactions used SYBR Green
master mix (Qiagen) following the manufacturer’s instructions.
Transcript abundance in individual samples was quantiﬁed using
the StepOne® Real-Time PCR System (Applied Biosystems,Carls-
bad, CA, USA) in comparison toa5p o i n tstandard curve gen-
erated from pooled sample aliquots. Biological triplicates (the
same samples used for microarray analysis described below) were
generated for each experimental condition, with each triplicate
sampleassayedbyquantitativereal-timePCR(qRT-PCR)indupli-
cate. PCR primer sequences (represented 5 –3 ) used in validation
experiments are shown in Table S2 in Supplementary Material. In
addition to RNA from cultured cells, initial experiments assayed
human substantia nigra RNA for purposes of comparison. To this
end, 30 fresh-frozen human midbrains were cryostat-sectioned,
slide-mounted, and ﬁnely dissected to enrich for substantia nigra
DA neurons as compared to surrounding non-DA cell groups.
Two independent pools of human RNA were generated by pool-
ingequalRNAaliquotsfrom15specimenseach(NB:de-identiﬁed
cadaverspecimenswereobtainedatautopsyandthereforenot con-
sidered human subjects research or governed by 45 CFR part 46,
per SF424 guide Part II: Human Subjects).
GENE EXPRESSION ANALYSIS
Microarray assays (using HT-12 BeadChips; Illumina, Inc., San
Diego,CA,USA)wereperformedbytheKeckMicroarrayResource
aspartoftheNIHNeuroscienceMicroarrayConsortium.Rawand
quantile-normalized microarray data and an associated project
metadata ﬁle are available through the NCBI-GEO repository
(GSE33434). The quality and quantity of each RNA sample
(aliquots of the same samples used for qRT-PCR experiments
describedabove)wasveriﬁedusinganAgilentBioanalyzer(Agilent
Technologies, Santa Clara, CA, USA) prior to labeling reactions.
Biotin-labeled cRNAs were generated using the TotalPrep RNA
Ampliﬁcation kit (Applied Biosystems) with 500ng total RNA as
template. Each sample was labeled in an independent reaction,
with n =3 biological replicates for each cell line. Microarray con-
trols included control RNAs spiked into RT reactions, as well as
spiked-in cRNAs that matched or mismatched with BeadChips
oligos. Labeled cRNAs were hybridized according to the man-
ufacturer’s protocol and scanned on the Illumina iScan. Initial
Consortiumdataanalysisincludedquantilenormalization,carried
out in Illumina BeadStudio.
STATISTICAL AND BIOINFORMATIC ANALYSES
Normalized array data for biological triplicates (see above) was
importedintoMultiExperimentViewer(MeV)1 andsampleshier-
archically clustered by Pearson correlation to investigate replicate
similarity and identify any potential outliers. Biological tripli-
cates of each clonal line were found to be more closely correlated
with each other than with triplicates from the other clonal lines
(Figure A2 in Appendix), establishing a high degree of repro-
ducibility in the proﬁles of gene expression among samples from
the same clonal line; all microarray data were thus included in
all subsequent analyses. A one-way ANOVA of the normalized
array data was carried out (in MeV) for all transcripts exhibit-
ing at least a 20% change in the E and/or G clonal lines relative
to the C line [NB: in our validation experiments, we were able
to validate changes <20% (see Figure 3; Table S1 in Supple-
mentary Material)].After a Benjamini–Hochberg multiple testing
correction, we identiﬁed ∼6100 transcripts exhibiting signiﬁcant
differences (corrected p ≤0.05) as a function of NURR1 expres-
sion (Table S1 in Supplementary Material). This list of transcripts
was imported into Microsoft Excel and further classiﬁed based
on their response proﬁle across clonal lines (Figure2).A subset of
1http://www.tm4.org/mev/
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transcriptsmostrobustlyaffectedbyNURR1over-expression(i.e.,
those transcripts exhibiting at least a twofold increase/decrease in
clonal lines E or G relative to C) was hierarchically clustered by
Pearson correlation (in MeV) to identify subsets of coordinately
regulated transcripts (Figure 4). The resulting transcript clusters
were imported into Genomatix Software Suite (v2.1)2 and ana-
lyzedinthePathwaySystem(GePS)moduletodetectsigniﬁcantly
enriched gene ontology (GO) biological processes (p ≤0.01, see
Figure 4). In addition, the list of NURR1-responsive transcripts
in the clonal cell lines (Table S1 in Supplementary Material) was
compared with those transcripts co-varying with NURR1 gene
expression in human substantia nigra (as determined by Pavlidis
template matching to NURR1 transcript abundance across sub-
jects in MeV (at the p <0.05 level). The enrichment for GO terms
(p <0.01) in the resulting set of 897 overlapping probes (deter-
mined in Genomatix) is shown in Table S3 in Supplementary
Material.
RESULTS
GENERATION AND CHARACTERIZATION OF A MODEL SYSTEM FOR
STUDYING NURR1-MEDIATED EFFECTS
In order to facilitate our investigation into the proﬁle of NURR1-
responsive transcripts as well as the possible concentration-
dependent effects of NURR1, we generated stable SK-N-AS-
derivedclonalcelllineswithdifferentlevelsofNURR1geneexpres-
sion in an otherwise identical cellular background (Figure 1).
A clonal line derived using empty expression vector (designated
C cells) exhibited low basal levels of NURR1 gene expression
2http://www.genomatix.de/en/index.html
FIGURE 1 | Generation of neural cell lines with graded expression of
the transcription factor NURR1. NURR1 gene expression in
SK-N-AS-derived clonal lines E and G bracketed that seen in human
substantia nigra, whereas acute NURR1 induction in the MN9D cell model
was several orders of magnitude higher than seen in human tissue. Bars
are the means (±SD) of biological triplicates (C, E, G cells) or single
samples (MN9D and human SN pools) measured by qRT-PCR in duplicate.
The two human SN pools were comprised of 15 independent specimens
each. Note that data are plotted on a log scale. ∗Indicates signiﬁcant
difference in NURR1 expression compared to control (C cells; one-tailed
t-test, p ≤0.003).
(Figure 1), as previously reported for parental SK-N-AS cells
(Michelhaugh et al., 2005; Wang and Bannon, 2005; Wang et al.,
2007). Statistically signiﬁcant increases in NURR1 gene expres-
sionwereevidentinclonallineswithNURR1-encodingtransgene
(designated E and G cells; Figure1) accompanied, as expected, by
increasesinnuclearlevelsofNURR1protein(FigureA1inAppen-
dix). To provide a physiological context for the level of NURR1
gene expression, SK-N-AS clonal lines were compared with sam-
ples of human substantia nigra (a brain region highly enriched
in NURR1-expressing DA neurons) as well as a mouse neural cell
line commonly used to study NURR1 effects (i.e., MN9D cells
with a doxycycline-induced Nurr1 transgene; Luo et al., 2007). As
shown in Figure 1, NURR1 gene expression in the E and G clonal
lines bracketed that seen in human substantia nigra, whereas its
expression in doxycycline-treated MN9D cells was actually several
orders of magnitude higher than that seen in brain tissue. These
datasuggestthatproﬁlingthedifferencesingeneexpressionacross
theseC,E,andGclonallinesmightprovideamorerelevantmodel
of NURR1-dependentchangesingeneexpressionoccurringinthe
human brain during DA cell development and DA-related disease
states.
NURR1-RESPONSIVE TRANSCRIPTS EXHIBIT DIFFERENCES IN
CONCENTRATION-DEPENDENCE AND DIRECTIONALITY OF CHANGE
We identiﬁed by microarray analysis >6000 transcripts (corre-
spondingto∼5000genes)whoseabundancedifferedsigniﬁcantly
(one-way ANOVA; corrected p ≤0.05) in response to increasing
NURR1expression.Acompletelistofthesedifferentiallyexpressed
transcripts (and corresponding fold changes) is provided in Table
S1 in Supplementary Material. As summarized in Figure 2,
NURR1-induced similar magnitude increases and decreases in
equivalent numbers of transcripts (compare Figures 2A,B). It
was noteworthy, however, that for many transcripts, the effects
of NURR1 actually varied as a function of its concentration; for
example,one-ﬁfthof NURR1-responsivetranscriptsshowedbidi-
rectional changes with increasing NURR1 expression (Table S1 in
SupplementaryMaterial).Overall,thesedatastronglysuggestthat
NURR1exertspreviouslyunrecognizedconcentration-dependent
effects.
We validated these microarray ﬁndings using qRT-PCR. For
every transcript that was examined in this manner, qRT-PCR
dataweresigniﬁcantlycorrelatedwiththecorrespondingmicroar-
ray data (Figure 3). This was the case irrespective of whether a
given transcript was a well-established NURR1 target [e.g., solute
carrier family 6 member 3 (SLC6A3; aka DAT1), dopa decar-
boxylase (DDC), alpha-synuclein (SNCA), or vasoactive intesti-
nal polypeptide (VIP)], a suspected but less well-characterized
NURR1 target [e.g., carboxypeptidase E (CPE)], or a new
NURR1 target as identiﬁed in this study [e.g., apolipoprotein
E( APOE), CCAT/enhancer protein beta (CEBPB), chemokine
(C-X-C motif) ligand 12 (CXCL12), or early growth response
p r o t e i n1( EGR1); see Figure 3]. Importantly, changes in tran-
script abundance were validated whether unidirectional (APOE,
CPE, DDC, EGR1, SLC6A3, SNCA) or bi-directional (CEBPB,
CXCL12, VIP) as a function of NURR1 concentration, spanning
magnitudesofchangerangingfrom<20%to>10-folddifferences
(Figure 3). These qRT-PCR data strongly support the validity
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FIGURE 2 | Summary of NURR1 effects on proﬁles of gene expression.
The abundances of >6000 transcripts were signiﬁcantly altered as a
function of increasing NURR1 concentrations across SK-N-AS-derived
clonal lines (i.e., C→E→G lines).Transcripts exhibiting a unidirectional
response to increasing NURR1 [i.e., increased in E and G (A) or decreased
in E and G (B), relative to C] are characterized by distributions of effect sizes
(fold-change plotted on x axis, percent of transcripts with corresponding
change plotted on y axis). Not shown are the one-ﬁfth of NURR1-responsive
transcripts that exhibited bidirectional changes with increasing nurr1
expression (i.e., different directions of change in E and G, relative to C; see
Table S1 in Supplementary Material for supporting expression data).
of the larger microarray dataset (Table S1 in Supplementary
Material).
Table 1 (left-hand column) lists NURR1-responsive genes
found in our gene proﬁling dataset (Table S1 in Supplemen-
tary Material) that have been previously characterized as NURR1
targets based on some combination of experimental approaches
(including NURR1 over-expression, Nurr1 gene knockout, ChIP-
on-chip, and/or promoter analysis). Also indicated (in the center
and right-hand columns) are NURR1-responsive genes seen in
our proﬁling dataset that had been previously suggested as possi-
ble NURR1 targets based on more limited evidence (i.e.,solely on
differential expression in the Nurr1 knockout mouse or NURR1
ChIP-on-chip data; Table 1; Sacchetti et al., 1999, 2001; Iwawaki
et al., 2000; Wallen et al., 2001; Hermanson et al., 2003, 2006;
Lammi et al., 2004; Davies et al., 2005; Gil et al., 2007; Kitagawa
et al., 2007; Luo et al., 2007; Sousa et al., 2007; Volpicelli et al.,
2007; Yang and Latchman, 2008; Jacobs et al., 2009a; Galleguil-
los et al., 2010). The magnitude and directionality of NURR1-
responsiveness we observed in these latter groups was the same
as that seen for more well-documented NURR1 targets,providing
conﬁrmatory biological evidence in support of their inclusion as
members of an expanded list of NURR1-responsive genes.
RELATIONSHIPS AMONG THE MOST ROBUSTLY AFFECTED NURR1
TARGETS
Given the number of NURR1-responsive transcripts identiﬁed in
Table S1 in Supplementary Material, this list most likely encom-
passes both many direct targets of NURR1 as well as genes lying
downstream of NURR1 action. In order to focus on those more
likely to be direct NURR1 targets, we narrowed our subsequent
investigation to the subset of transcripts most robustly affected by
NURR1 over-expression. In this instance, we selected the ∼1700
transcripts (representing ∼1400 genes) from our larger dataset
(Table S1 in Supplementary Material) that exhibited at least a
twofold difference in abundance in either the E or G cells (rel-
ative to C). To identify potential relationships among NURR1-
responsive genes and the potential signiﬁcance of different pat-
terns of NURR1-responsiveness, we hierarchically clustered this
subset of transcripts by Pearson correlation, identifying groups
showing similar expression patterns across clonal cell lines. We
found that these most highly NURR1-responsive transcripts fell
into ﬁve broad clusters,for which the direction and magnitude of
change in abundance is indicated in Figure4 (left-hand portion).
The biological processes and some of the transcripts represented
in these clusters are described below.
Cluster 1 (Figure 4) consists of transcripts maximally or near-
maximally induced by moderate changes in NURR1 (i.e., C
line→E line). More robust NURR1 gene expression (e.g., seen
in the G line) induced no further (or only incremental) increases
in target gene expression (or in a few cases, actual decreases).
GO analysis indicated that the biological processes most enriched
in this transcript cluster are related to nervous system devel-
opment (Figure 4, right side). Some examples of these highly
NURR1-responsive transcripts include collapsing response medi-
ator1(CRMP1;aneuronal-speciﬁcregulatorof sema3Asignaling
in growth cones), kinesin family member 1A (KIF1A; involved in
axonal transport of synaptic vesicles), tubulin 2beta and 2alpha
(TUBB2B andTUBB2A;majormicrotubulecomponentsinvolved
in neuronal migration and vesicle movement), embryonic lethal,
abnormal vision, Drosophila-like 3 and trinucleotide repeat con-
taining 4 (ELAVL3 and TNRC4; neuron-speciﬁc RNA-binding
proteins) and BR serine/threonine kinase 1 (BRSK1; a protein
kinase critical for development of neuronal polarization).
Cluster 2 (Figure 4) consists primarily of transcripts best
characterized by their prominent induction in response to only
higher NURR1 expression (i.e., G line). The transcripts most
enrichedinthisclusterFigureinratherbroadbiologicalprocesses,
including responses to external stimuli, and the regulation of
cell development and localization. Included within the cluster are
many transcription factors,including immediate early genes [e.g.,
EGR1, FBJ murine osteosarcoma viral oncogene homolog (FOS),
jun proto-oncogene (JUN)], developmental transcription factors
[e.g., gastrulation brain homeobox 2 (GBX2), LIM homeobox 8
(LHX8), homeobox C8 (HOXC8), neurogenin 2 (NEUROG2)],
andotherclassesof transcriptionfactors[e.g.,cAMPresponseele-
ment binding protein 5 (CREB5), CEBP delta (CEBPD)]. These
NURR1-induced transcription factors may, in turn, contribute
to activation of biological processes linked to this cluster. A dis-
tinct subgroup of transcripts within cluster 2 were unchanged or
decreased somewhat in abundance by moderate NURR1 levels
(e.g., E cells), but robustly induced with greater NURR1 concen-
trations(Figure4).Anumberofthesetranscripts[e.g.,interleukin
1beta(IL1B),leukemiainhibitoryfactor(LIF),tumornecrosisfac-
tor alpha-induced protein 6 (TNFAIP6), chemokine (C-C motif)
ligand 7 (CCL7),interleukin 8 (IL8),prostaglandin-endoperoxide
synthase2(PTGS2),matrixmetalloproteinase9(MMP9)]encode
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FIGURE 3 |Validation of individual NURR1 target genes identiﬁed by
microarray.The abundance of representative NURR1-responsive
transcripts was determined by qRT-PCR. In each case examined, transcript
abundance across clonal cell lines was signiﬁcantly correlated with the
corresponding microarray data, irrespective of the magnitude or direction
of NURR1-responsiveness, or whether the transcript was a previously
known or novel NURR1 target. Data from triplicate samples used in
microarray and qRT-PCR assays are shown (microarray intensity values on
y axis, qRT-PCR data reported on x axis in arbitrary units). For each
transcript, corresponding Pearson r values are indicated; data were
signiﬁcantly correlated (one-tailed p ≤0.005). Different shaded arrows
indicate biological triplicates of the clonal lines (C, E, or G) from which
samples were derived. Primer sequences are provided inTable S2 in
Supplementary Material.
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Table 1 | Known and putative NURR1 target genes showing
NURR1-dependent differential expression in clonal cells.
Established Knockout ChIP-on-chip
ATF3 ACOT1 PBX1 ACSL3 SFRS3
ATF5 AKAP13 PDLIM7 ARID3B SSBP3
AUH ALCAM PLEKHG3 ARID5B STMN4
BDNF ANAPC2 PRMT1 BAI3 TEAD2
CCL2 ANKRD10 PTPRR BCCIP TMEM98
CCL7 ATP6V0C RALGPS1 BRSK1 TRIB2
COL4A1 BID RDM1 CDC42BPB TRPM8
DDC BRD9 RPL15 CDK5RAP2 TSC22D1
DLK1 BTG1 RPL29 CHM TUBB2A
EPS8 C6orf72 SEMA3A CHN1 TUBB2B
FEZ1 CCDC107 SF3B5 CPE UBTF
GCH1 CCNL1 SHANK3 DDEF2 UROS
HIST1H1C CKB SLC25A23 DYNLT1 ZNF260
IGFBP5 CLIC1 SNCAIP ELAVL4 ZNF580
IL8 CNTN6 TAF2 FSHB ZWINT
MEST COMMD9 TAF6L GABBR1
MMD CRABP1 TAF9 GPC2
NASP CRIPT TBC1D9B ITPR1
NEFM CTGF TCF25 KCTD15
NEK2 CTNNAL1 TMED3 LILRB3
NGF CUL1 TNFRSF19 LMTK3
NRP1 DNMT1 TRIM21 LPHN3
PPM1A DYNC1I2 TTC28 MAGEA2
PTP4A3 EGFLAM TXNL4B MAP2
RET ELMO3 USP36 MAST1
RHOQ ETFB XIST MTUS1
SCG3 GDI2 ZNF503 NFKBIB
SGSM1 GRIPAP1 NUP62
SLC6A3 IRX5 PHB
SMPDL3A KCNJ8 PHLDB2
SNAI2 LAMP1 PLD3
SNCA LTA4H PRCP
SPP1 LZTR1 PSMD8
STC2 MRPL52 PXDN
TCF7L2 NAV1 RGS2
TNC NFYC RTN1
TUBB3 NQO1 RUNX1T1
VIP NRAS SEMA6A
Established NURR1 target genes were previously identiﬁed based on some
combination of NURR1 over-expression, gene knockout, ChIP-on-chip, promoter
analysis, and/or other experimental approaches (left column). Putative target
genes were previously identiﬁed based on evidence from Nurr1 gene knockout
or ChIP-on-chip alone (middle and right columns, respectively).
prototypical pro-inﬂammatory proteins; many of these, however,
exert context-dependent effects on neuronal development,migra-
tion,plasticity,orsurvivalaswell(Boulanger,2009;Devermanand
Patterson, 2009).
Cluster 3 (Figure4) consists of a small but interesting group of
transcriptsrobustlydecreasedinresponsetoevenmodestincreases
in NURR1 (C→E), but which rebounded to near-control levels
of abundance in the presence of higher NURR1 concentrations
(i.e., G cells). The biological processes represented in this clus-
ter are related to immune response [e.g., chemokine (C-C motif)
ligand 2 (CCL2), complement component 3 (C3), complement
component1r-subcomponent-like(C1RL),interleukin32(IL32),
serum amyloid A1 (SAA1)] and, to a lesser extent, angiogene-
sis. Cluster 4 (Figure 4) consists of a larger group of transcripts
decreasedinabundancefollowingall increasesinNURR1concen-
tration examined (i.e., C→E, G). Biological processes related to
antigen processing/presentation and immune response are very
highly enriched in this cluster, including transporter 1, ATP-
binding cassette, subfamily B (TAP)-related transcripts (TAP1,
TAP2,TAPBP,TAPBPL),human leukocyte antigen (HLA)-related
transcripts(HLA-A,HLA-A29.1,HLA-B,HLA-F,HLA-H),nuclear
factor kappa B (NFKB)-related transcripts (NFKB1, NFKBIA),
TNF-related transcripts (TNF, TNFIP1, TNFRSF4), peroxisome
proliferator-activatedreceptorgamma(PPARG),andcomplement
component 7 (C7), among others.
Cluster 5 (Figure 4) consists of transcripts slightly decreased
(or less frequently, slightly increased) in abundance by mod-
erate increases in NURR1, but substantially reduced at higher
NURR1 concentrations (e.g., C line→G line). The most highly
enriched biological categories relate to nucleic acid metabolic
processes, DNA replication, and cell cycle; some speciﬁc tran-
scripts include minichromosome maintenance complex compo-
nent(MCM)-relatedtranscripts(MCM4,MCM5,MCM6,MCM7,
MCM10), heterogeneous nuclear ribonucleoprotein (HNRNP)-
related transcripts (HNRNPA1, HNRPH1, HNRPK, HNRPM),
and cell division cycle (CDC)-related transcripts (CDC14B,
CDC45L,CDCA7).Overall,hierarchicalclusteringandGOanaly-
sesrevealedthatgroupsoftranscriptsthatclusteredtogetherbased
on their concentration-dependent responses to NURR1 appear to
subserve quite distinct biological processes.
DISCUSSION
For our investigation into the nature of NURR1-responsive genes,
we generated stable clonal cells lines with graded NURR1 expres-
sionthatapproximatedthatseeninhumansubstantianigra(i.e.,E
and G lines; Figure 1). Hierarchical clustering of gene expression
data from biological triplicates of these clonal lines (and an addi-
tional, independent NURR1-expressing clonal line) conﬁrmed
that the changes in NURR1 abundance per se largely accounted
fortheobserveddifferencesingeneexpressionproﬁles(FigureA2
in Appendix). Examining the different proﬁles of gene expres-
sion seen with increasing NURR1 concentration (i.e., C→E, G)
provides a new cellular model of NURR1-related changes sim-
ilar to those occurring during DA cell development; conversely,
gene expression changes seen with decreasing NURR1 (i.e., G,
E→C) may model some of the changes seen during the course
of DA-related neurodegenerative disease states, particularly those
involving loss of NURR1 expression (e.g., PD and drug abuse).
In this regard, it may be worth noting that, although there are
important differences between our SK-N-AS-derived clonal lines
and authentic DA neurons, the biological processes most affected
(i.e., GO terms most enriched) in our clonal cells as a function
of NURR1 expression (Figure 4) are similar to the GO terms best
describing human substantia nigra transcripts that co-vary with
NURR1 gene expression (Table S3 in Supplementary Material).
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FIGURE 4 | Hierarchical clustering of the most robustly affected
NURR1-responsive transcripts identiﬁed clusters with distinct
concentration-dependence and biological processes.Transcripts
included in this clustering were increased or decreased at least twofold in
either the E or G cell line (relative to C, ∼1700 transcripts).The resulting ﬁve
distinct clusters are indicated, with the direction (red, increased; green,
decreased) and magnitude of change (color intensity) indicated (left-hand
portion).The top biological processes most enriched in each of the ﬁve
clusters (along with corresponding GO ID terms and p values) are presented
(right-hand portion).
A central ﬁnding of the present study was that NURR1 effects
are concentration- and gene-dependent: different patterns of
increased or decreased transcript abundance (and even some
bidirectional changes) were seen as a function of NURR1 concen-
tration (Figures 2–4; Table S1 in Supplementary Material). Our
data indicate that conﬂicting reports in the literature regarding
the NURR1-responsiveness of individual genes may well reﬂect
heretofore unappreciated differences in the magnitude of NURR1
induction obtained in various model systems. In a similar vein,
the recent observation (Jacobs et al., 2009a) that numerous tran-
scriptsweresimilarlychangedbythecompleteloss of NURR1and
NURR1 over-expression seems consistent with our ﬁnding that
some transcripts respond to NURR1 in a bidirectional manner.
The fact that our microarray ﬁndings were validated by qRT-PCR
irrespective of the direction or magnitude of change (Figure 3)
supports the overarching conclusion that NURR1 exerts gene-
speciﬁc,concentration-dependent(andsometimesbi-directional)
effects.
Although this is the ﬁrst report of concentration-dependent
responses to NURR1, a similar phenomenon has been reported
for the hematopoietic transcription factors GATA-1 and Pu.1,
where the responsiveness of target genes is thought to be linked
to variations in response element sequences or location and/or
by interactions with multiple co-regulators (Johnson et al., 2006;
Kamath et al., 2008; Pope and Bresnick, 2010). In this regard,
it is interesting to note that, in addition to its well-established
role in neurogenesis, NURR1 has recently been implicated in
control of hematopoietic stem cell proliferation (Sirin et al.,
2010). Although it is well-known that NURR1 (and family mem-
bers NUR77 and NOR-1) can regulate target gene expression
through binding as a monomer, homodimer, or heterodimer to
a number of related cis-elements (Maxwell and Muscat, 2005),
we were unable to identify consistent differences in the nature,
frequency or location of cis-elements that predicted the observed
magnitude or pattern of NURR1 response of previously known
or newly identiﬁed NURR1-responsive genes (not shown). On
the other hand, there is a nascent appreciation that NURR1
also interacts with a number of distinct co-regulators (Mulhol-
land et al., 2005; Sacchetti et al., 2006; Carpentier et al., 2008;
Jacobs et al., 2009b); the role of these different co-regulators
in NURR1’s pleiotropic, concentration-dependent effects thus
warrants further investigation.
In the current experiments, we observed that even modest
increasesinNURR1abundanceresultedinincreasedexpressionof
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transcriptsrelatedtoNURR1’swell-appreciatedroleinDAneuron
development and maintenance (Figure4; cluster 1 and,to a lesser
extent,cluster 2).A correlate of the apparent commitment toward
neurogenesis was a NURR1-induced, concentration-dependent
decreaseintheexpressionof genesinvolvedinprocessesrelatedto
cell division (Figure4; cluster 5),resulting in a lengthening of cell
doubling times with increasing NURR1 levels (i.e., C line: 24h; E
line: 58h; G line 72h doubling times, respectively); similar ﬁnd-
ings have been previously described in a neural stem cell context
(Sousa et al., 2007). On the other hand, a strong but more com-
plex concentration-dependent effect of NURR1 was observed for
numerous immune-related transcripts, in that modest increases
in NURR1 signiﬁcantly reduced their expression levels, whereas
further increases in NURR1 resulted in lesser decreases (or in
some cases, clear increases) in gene expression (Figure 4; clusters
3, 4 and a subgroup of cluster 2). This is particularly interest-
ing given that NURR1 has been implicated as a mediator of
immune/pro-inﬂammatory processes in some peripheral tissues
and animal models of multiple sclerosis (McEvoy et al., 2002;
Davies et al., 2005; Doi et al., 2008), whereas NURR1 exerts anti-
inﬂammatoryeffectsinotherperipheraltissues(Bontaetal.,2007)
and neuroprotective effects on DA cells in inﬂammatory mod-
els of PD (Saijo et al., 2009). Although some NURR1-induced
“pro-inﬂammatory”proteinscan,undercertainconditions,medi-
ateadditionalnon-inﬂammatoryeffects(e.g.,neuronalmigration,
differentiation or neuroprotection; Carvey et al., 2001; Littlejohn
et al., 2011), our data are also consistent with the notion that
increasing NURR1 concentrations could, in some instances, tip
the scales from anti-inﬂammatory to pro-inﬂammatory cellular
effects. Our working hypothesis is that high levels of NURR1 are
associated with its role as a stimulus-induced immediate early
gene which,while physiologically adaptive in the short-run,could
mediate detrimental biological processes (e.g., chronic inﬂam-
mation, immune response, apoptosis) over extended periods of
time. On the other hand, modest levels of NURR1 may be all
that is needed to facilitate neurogenesis, inhibit cell cycle pro-
gression, stabilize neural phenotype, and dampen immune and
pro-inﬂammatory processes.
Ourresultsshowthat,beyonditspreviouslydescribedeffectson
afewknownDAphenotypicgenes,NURR1cansigniﬁcantlyaffect
theexpressionof manyotherneuralgenes,someimplicatedinthe
function (or dysfunction) of DA neurons (see Figure 5; support-
ive expression data found in Figure 3; Table S1 in Supplementary
Material). For example, NURR1 induces expression of numerous
transcription factors and their co-regulators, including TCF7L2,
a known NURR1 target and Wnt signal transducer involved in
DA cell development (Jacobs et al., 2009a) and EGR1, which
increasesDAsynthesis(PapanikolaouandSabban,2000).NURR1
also induced both CREB5 and CREBBP (CBP), thus constituting
a feed-forward system, given that NURR1 is itself a highly CREB-
responsivegene(Volakakisetal.,2010).WealsofoundthatNURR1
regulatesnumerousgenesencodingneuron-speciﬁcRNA-binding
proteinsincludingELAVL4,ageneconsistentlyassociatedwithrisk
of PD (Noureddine et al., 2005; DeStefano et al., 2008). NURR1
regulates numerous genes involved in dendritic, axonal, vesicular,
and exocytotic functions including SEMA3A, which is critical to
thenavigationof DAaxons(Hernandez-Montieletal.,2008;Torre
FIGURE5|S c hematic representation of multiple sites of action
through which NURR1 regulation of gene expression may contribute
to DA cell development, phenotypic stability, neuroprotection or
functional recovery. Some speciﬁc genes robustly regulated by NURR1
are grouped according to their primary biological processes; many are
known to modulate DA neuronal activity and/or have been associated with
DA-related diseases such as Parkinson’s disease or drug abuse.
Abbreviations for gene names are indicated in the text and supportive gene
expression data are provided inTable S1 in Supplementary Material.
etal.,2010),andKIF1A,amotorproteinwhosealteredabundance
precedes DA axon neuropathy and DA cell loss in a mutant SNCA
m o d e lo fP D( Chung et al., 2009). In addition, NURR1 regulates
numerousDAcelltrophicfactors,includingGDF15,whichrescues
DAcellfunctioninginamodelofPD(Strelauetal.,2000).NURR1
alsoregulatestheCXCL12–CXCR4signalingpathway,whichmod-
ulates DA cell activity and cocaine-induced (i.e., DA-mediated)
behavior, and whose robust expression in DA cells is altered in
both a model of PD and clinical PD (Guyon et al., 2008; Shi-
moji et al., 2009; Trecki and Unterwald, 2009). We report for the
ﬁrst time that NURR1 robustly induces expression of APOE, for
whichthe 4variantisassociatedwiththeriskof bothAlzheimer’s
disease and loss of brain DA (Camicioli et al., 1999). We also
note that nurr1 co-regulates SLC6A3 (encoding the DA trans-
porter) as well as the DA transporter-binding proteins (Sidhu
et al., 2004; Zhang et al., 2009) SNCA and CPE; the former two
genes having established associations with PD, drug abuse, and
otherneurologicaldisorders(Bannon,2005;Vendaetal.,2010).In
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summary, these data support the promise of NURR1-based CNS
therapeutics for the functional restoration and neuroprotection
of DA neurons, particularly if therapeutic strategies can encom-
passtheongoingadvancesincell-speciﬁctargetingtoDAneurons
(Gonzalez-Barrios et al.,2006).
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APPENDIX
FIGUREA1 | Immunocytochemical demonstration of increased NURR1
abundance in SK-N-AS-derived clonal cell lines E and G. Note that both
endogenous NURR1 (in C cells; top) and transgene-derived NURR1 (in E
and G! cells: middle and bottom panels, respectively) is primarily nuclear in
(Continued)
FIGUREA1 | Continued
localization. Cells were ﬁxed with cold 4% paraformaldehyde for 30
minutes and blocked for 2h at 4˚C (PBS with 5% normal goal serum. 5%
normal donkey serum. 2% BSA, and 0.2%Triton ×-100) before incubation
at 4˚C overnight with NURR1 antibody at 1:200 dilution in blocking solution
(N20: Santa Cruz Biotechnology, Santa Cruz, CA, USA). After rinsing, cells
were incubated with a 1:500 dilution (in blocking solution) of biotinylated
anti-rabbit secondary antibody (Vector Laboratories, Burlingame, CA, USA)
and diaminobenzidine peroxidase substrate kit with nickel enhancement
(Vector Laboratories) per the manufacturer’s protocols. Semi-quantitative
assessment of 50 NURR1-positive cells from each clonal line (captured
from multiple immunocytochemical images, each background-corrected)
revealed that the increase in nuclear NURR1 abundance in E cells (∼2.4-fold
relative to C cells) paralleled the changes seen in transcript abundance (see
Figure 1). Although larger increases in NURR1 immunoreactivity were
visually apparent in G cells (bottom panel) compared to C or E cells, the
extent of increase in abundance (nominally measured as ∼3.3-fold increase
over C) could not be accurately quantiﬁed due to the obvious saturation of
the NURR1 immunocytochemical signal. Scale bar represents 25μm.
FIGUREA2 | Hierarchical clustering of samples by Pearson correlation
demonstrates that NURR1 expression is the major determinant of
relatedness of gene expression proﬁles among clonal cell lines. Proﬁles
of gene expression were compared for biological triplicates of clonal C. E, G
cells and an additional clonal cell line (D) we isolated with NURR1 transcript
abundance equivalent to G cells (Ct of 27 .0 versus 26.9, respectively, by
qRT-PCR). Clustering by Pearson (Pearson r indicated on vertical axis)
shows that biological triplicates for each cell line are most highly related,
that C cells stand apart from the NURR1-transgene expressing cells, and
that the G and D lines are most highly related, verifying that changes in
NURR1 abundance per se could largely account for observed differences in
patterns of gene expression.
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